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Quantitative lateral flow strip 
assays as User-Friendly Tools To 
Detect Biomarker Profiles For 
Leprosy
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Louis Wilson1, Claudia J. de Dood2, Roel Faber3, Korshed Alam4,  Jan Hendrik Richardus3, 
Paul L. A. M. Corstjens2 & Annemieke Geluk1
Leprosy is a debilitating, infectious disease caused by Mycobacterium leprae. Despite the availability 
of multidrug therapy, transmission is unremitting. Thus, early identification of M. leprae infection is 
essential to reduce transmission. The immune response to M. leprae is determined by host genetics, 
resulting in paucibacillary (PB) and multibacillary (MB) leprosy associated with dominant cellular or 
humoral immunity, respectively. This spectral pathology of leprosy compels detection of immunity to 
M. leprae to be based on multiple, diverse biomarkers. In this study we have applied quantitative user 
friendly lateral flow assays (LFAs) for four immune markers (anti-PGL-I antibodies, IL-10, CCL4 and 
IP-10) for whole blood samples from a longitudinal BCG vaccination field-trial in Bangladesh. Different 
biomarker profiles, in contrast to single markers, distinguished M. leprae infected from non-infected 
test groups, patients from household contacts (HHC) and endemic controls (EC), or MB from PB 
patients. The test protocol presented in this study merging detection of innate, adaptive cellular as well 
as humoral immunity, thus provides a convenient tool to measure specific biomarker profiles for  
M. leprae infection and leprosy utilizing a field-friendly technology.
Leprosy, a chronic infectious disease caused by Mycobacterium leprae (M. leprae) ranking second as the most 
pathogenic mycobacterial infectious disease after tuberculosis (TB), is still considered a major threat in develop-
ing countries1. The condition is characterized by skin lesions and damage to peripheral nerves, the hallmark of 
leprosy pathology often resulting in severe, life-long disabilities and associated stigma2,3.
Despite the remarkable decrease in prevalence following introduction of multidrug therapy, it remains 
challenging to further reduce transmission as substantiated by the stable global annual incidence around 200,000 
new cases for the past 10 years4. This continued transmission is largely due to M. leprae infected individuals 
lacking clinical symptoms5. In addition, identification of host-derived biomarkers for progression to dis-
ease is complicated by the low incidence and long incubation time requiring extensive, longitudinal studies. 
Furthermore, although molecular techniques to elicit strain differences within the leprosy bacillus are important 
diagnostic tools to enhance our understanding of the epidemiology of leprosy, differentiate between relapse and 
re-infection6–10, these pathogen-derived profiles are not suitable to indicate development of leprosy in infected, 
asymptomatic individuals.
These hurdles contributed to the current lack of tests for detection of asymptomatic M. leprae infection and 
diagnosis of early stage leprosy11. As clinical resistance to commonly used antibiotics in leprosy treatment is 
increasingly occurring12,13, such tests should be highly specific to prevent redundant use of antibiotics.
Clinical manifestations closely parallel cellular immunity to M. leprae such that leprosy presents as a charac-
teristic spectrum ranging from tuberculoid (TT) or paucibacillary (PB) leprosy to lepromatous (LL) or multi-
bacillary (MB) leprosy14. TT patients in general show strong T helper 1 cell (Th1) immunity with exacerbated 
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levels of pro-inflammatory cytokines and develop localized granulomatous disease with bacilli scarcely detect-
able in their lesions. At the opposite pole of the spectrum are LL patients who predominantly generate Th2 and 
anti-inflammatory cytokines such as interleukin-10 (IL-10) resulting in disseminating, progressive infections15. 
In between these two opposite poles of the leprosy spectrum, borderline states of leprosy [borderline tuberculoid 
(BT), borderline (BB) and borderline lepromatous (BL)] are positioned. Due to the diverse disease spectrum, 
detection of M. leprae infection in diagnostic tests requires multiple, diverse biomarkers specific for both cellular 
and humoral mediated immunity. In previous studies we have shown that IFN-γ -inducible protein 10 (IP-10) 
in response to a M. leprae-specific antigen (ML2478) correlates with M. leprae exposure and thereby the risk of 
infection and its subsequent transmission16. Additionally, we demonstrated that chemokine (C-C motif) ligand 
4 (CCL4), a component of the innate immunity, can be used to identify pathogenic immunity against M. leprae 
since it was increased in patients, partly in household contacts but not in endemic controls16. IL-10, on the other 
hand, is associated with suppression of Th1 cells in leprosy17–19. Moreover, most lepromatous patients with high 
bacillary loads produce antibodies against the M. leprae specific phenolic glycolipid I (PGL-I)20,21, which are 
hardly detected in PB22. Hence, sensitive tests that can simultaneously quantitate multiple analytes in one sample 
provide apt tools to characterize different clinical leprosy types. In particular, tests based on multicomponent host 
biomarker profiles that can identify M. leprae infected individuals (yet) without clinical symptoms of leprosy, will 
be useful for guidance of prophylactic treatment, thereby contributing to reduction of M. leprae transmission as 
well as prevention of disabilities.
Inherent to the situation in leprosy endemic areas is the absence of sophisticated laboratories. It is therefore 
imperative that new diagnostic tests are facilitated for application in the field. Up-converting phoshor lateral 
flow assays (UCP-LFAs) have previously shown to be robust, low-complexity assays, representing a field-friendly 
alternative for common laboratory-based ELISAs23,24, applicable for detection of multiple pathogens including 
food-borne pathogenic strains and potential biowarfare/bioterrorism agents25–27. Field evaluation of UCP-LFAs 
for detection of IL-10, IP-10, CCL4 and anti-PGL-I IgM demonstrated high correlation with ELISAs using sam-
ples from cohorts of limited numbers of leprosy- or TB patients28,29.
In the current study UCP-LFAs were applied to a more extensive (five-fold) sample size compared to our previ-
ous studies, derived from a randomized BCG vaccination field trial in Bangladesh30. Six test groups were included: 
MB patients, PB patients, healthy household contacts (HHC), HHC vaccinated with Bacillus Calmette-Guérin 
(BCG) (HHC&BCG), HHC who developed leprosy after BCG vaccination (new cases; NC) and endemic con-
trols (EC) from the same area without known contact with leprosy patients. This extended cohort study allowed 
exploratory identification of biomarker profiles for M. leprae infection, leprosy disease per se, the type of leprosy 
and BCG vaccination as determined with UCP-LFAs for the above indicated targets.
Results
Performance of the UCP-LFA versus ELISA. Whole blood samples (n = 726) from all individuals were 
analysed using ELISA, as well as the field-friendly UCP-LFAs for IL-10, IP-10, CCL4 and anti-PGL-I antibod-
ies. Comparison of UCP-LFA and ELISA results demonstrated significant correlation for all four biomarkers 
(p < 0.0001), confirming earlier observations28,29.
The diagnostic performance of the UCP-LFA in comparison to ELISA was further assessed through AUCs for 
the two most distinct phenotypes: MB patients (n = 34) and EC (n = 51). IL-10, IP-10 and CCL4 levels were deter-
mined in Nil, WCS and Mlep samples, as well as anti-PGL-I IgM levels (Fig. 1). The IL-10 and IP-10 UCP-LFAs 
outperformed the corresponding ELISAs, whereas the CCL4 and anti-PGL-I IgM tests performed equally. For 
discrimination of MB patients from EC, the proposed diagnostic field-tool UCP-LFA provides an equally well or 
even better alternative for the conventional ELISAs.
M. leprae specific responses based on single analyte UCP-LFA measurements. In order to put 
the quantitative test results obtained with the four single UCP-LFAs in the context of their biomarker potential, 
we assessed each analyte/stimulus combination by comparing median group levels. As indicated by the AUCs in 
Fig. 1, MB patients can be distinguished from EC based on IP-10 and CCL4 (irrespective of stimulus), anti-PGL-I 
IgM and IL-10WCS, therefore also showing significantly different median levels (Fig. 2, Table 1). Moreover, median 
levels of anti-PGL-I IgM and IP-10Nil differed between MB patients and (BCG-vaccinated) HHC, whereas median 
levels of IP-10WCS and CCL4WCS only distinguished the non-vaccinated HHC from MB patients. BCG vaccina-
tion therefore affects the immune response in HHC, as reflected by the significant difference in IP-10WCS levels 
between HHC and HHC&BCG (p = 0.018) (Fig. 2b). Furthermore, IL-10WCS levels differed between HHC and 
EC, while median levels of IP-10WCS and CCL4WCS differed between HHC&BCG and EC as well. PB patients and 
EC showed significantly different median CCL4Nil and CCL4WCS levels (Fig. 2c), as well as borderline significant 
different levels for IL-10WCS (p = 0.07) and IP-10WCS (p = 0.06).
The ability of each analyte/stimulus combination to distinguish between two groups is summarized in Table 1, 
thereby reviewing the biomarker potential of the four individual host immune markers. Remarkably, the levels of 
IP-10 (p < 0, 0001), IL-10 (p = 0.003) and CCL4 (p < 0.0001) in WCS stimulated samples were more significantly 
different for MB and EC than anti-PGL-I IgM levels (p = 0.0042). Moreover, anti-PGL-I IgM levels could not 
be used to discriminate PB patients or (BCG-vaccinated) HHC from EC, which clearly demonstrates the added 
value of IP-10, IL-10 and CCL4 in leprosy diagnostics.
Biomarker signatures to specify M. leprae infection, leprosy or disease classification. Diagnostic 
tests that allow detection of M. leprae infection, leprosy per se and leprosy classification would be of great benefit 
to the general healthcare in leprosy endemic areas. The four host immune markers allowed distinction between 
two groups (Table 1). However, to distinguish M. leprae infected from non-infected individuals or patients from 
healthy contacts, we compared host immune markers for multiple groups (Fig. 3).
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Figure 1. Discriminatory capacity of ELISA and UCP-LFA. To compare the ability of ELISA (dotted line) and 
UCP-LFA (solid line) to discriminate between individuals with or without disease ROC curves were computed 
using data of MB patients and EC. Areas under the curve (AUCs) were compared for all 10 conditions tested, 
shown in the lower right corner of each graph. (a) ROC curves for IP-10 stimulated and unstimulated samples 
based on concentration in pg/ml, showing an improved AUC for the UCP-LFA for IP-10Nil and IP-10WCS.  
(b) ROC curves for IL-10 stimulated and unstimulated samples based on concentration in pg/ml, showing an 
improved (IL-10Nil) or equal AUC for UCP-LFA. (c) ROC curves for CCL4 stimulated and unstimulated samples 
based on concentration in pg/ml, showing comparable values for UCP-LFA and ELISA. (d) ROC curves for 
anti-PGL-I IgM in unstimulated samples based on ratio, showing comparable AUCs for ELISA and UCP-LFA.
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Figure 2. Identification of M. leprae specific IL-10, IP-10, CCL4 and anti-PGL-I IgM antibodies by UCP-
LFA. (a) IL-10 concentrations (pg/ml) measured per group per stimulus show that MB patients, HHC and 
BCG-vaccinated HHC significantly differ from EC upon WCS stimulation. (b) IP-10 concentrations (pg/ml) 
measured per group per stimulus show that MB patients significantly differ from EC in both stimulated and 
unstimulated samples, from HHC in unstimulated and WCS stimulated samples and from BCG vaccinated 
HHC in unstimulated samples. BCG vaccinated HHC significantly differ from HHC and EC upon WCS 
stimulation. (c) CCL4 concentrations (pg/ml) measured per group, per stimulus show that MB patients 
significantly differ from EC in both stimulated and unstimulated samples and from HHC in WCS stimulated 
samples. PB patients significantly differ from EC in unstimulated and WCS stimulated samples and BCG 
vaccinated HHC significantly differ from EC in WCS stimulated samples. (d) anti-PGL-I IgM ratio measured 
per groups shows that MB patients have significantly higher levels of anti-PGL-I IgM compared to HHC, BCG 
vaccinated HHC and EC. P-values: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
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First, in order to combine immune markers into multicomponent host biomarker profiles, positive UCP-LFA 
results for each analyte/stimulus combination were collectively specified (Fig. 3; Supplementary Table S3). 
Second, analyte/stimulus combinations were selected such that they optimally distinguished individuals with 
a specified disease- or infection state (Fig. 3), considering all HHC as M. leprae infected. This resulted in three 
specific profiles:
(I) To indicate M. leprae infection we selected single test results obtained with IP-10Mlep, CCL4WCS and IL-10WCS 
UCP-LFAs as these analyte/stimulus combinations individually showed the least positive test results for EC 
compared to the M. leprae infected test groups (MB, PB, HHC and HHC&BCG) (Fig. 3). The combination 
of IP-10Mlep, CCL4WCS and IL-10WCS indeed was more frequently positive for MB/PB patients and (BCG-vac-
cinated) HHC than EC (Fig. 4a). Moreover, AUCs confirmed discrimination between non-infected and M. 
leprae infected test groups based on this multicomponent host immune profile (AUCs: 0.84 (MB vs. EC), 
0.75 (PB vs. EC), 0.7 (HHC vs. EC) and 0.71 (HHC&BCG vs. EC) (Supplementary Table S4A).
MB vs HHC MB vs HHC&BCG MB vs EC PB vs EC HHC vs EC HHC&BCG vs EC HHC&BCG vs HHC
anti-PGL-I IgM + + + + + + − − − − 
IP-10 + + + + + + − − − − 
IP-10 WCS + + + + − + + + + − − + + + 
IP-10 M. leprae proteins − − + − − − − 
IL-10 − − − − − − − 
IL-10 WCS − − + + + − + + + − 
IL-10 M. leprae proteins − − − − − − − 
CCL4 − − + + − − − 
CCL4 WCS + + − + + + + + − + + − 
CCL4 M. leprae proteins − − + − − − − 
Table 1.  Discriminatory biomarkers with potential for leprosy diagnostics. Differences in IP-10, IL-10, 
CCL4 and anti-PGL-I IgM levels between various test groups detected by UCP-LFA are provided. Each row 
represents one of the 10 different analyte/stimulus combinations measured. Each column shows the potential 
to distinguish the test groups indicated, only displaying the groups for which significant differences were 
observed: − p ≥ 0.05 indicates inability to distinguish test groups, + p ≤ 0.05, + + p ≤ 0.01, + + + p ≤ 0.001,  
+ + + + p ≤ 0.0001 indicating increasing capacity to distinguish test groups. Using one or multiple analyte/
stimulus combination MB patients could be distinguished from (BCG-vaccinated) HHC and EC, whereas PB 
patients and BCG-vaccinated HHC could be distinguished from EC.
Figure 3. Positive test results per analyte/stimulus combination used to construct potential biomarker 
profiles. The groups that should be differentiated to indicate M. leprae infection, disease per se and disease 
classification are shown. The potential profiles indicated are based on the percentage of positive individuals 
of these particular groups. The cut-off for positivity was based on values for NEC (Supplementary Table S3) 
per analyte/stimulus combination the percentage of individuals with a positive test result per group is shown. 
Based on these data the optimal analyte/stimulus combination to differentiate either infected from non-infected 
groups, patients and non-patients groups or MB and PB patients were selected to construct the potential profiles 
described.
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(II)  To detect leprosy patients from healthy, though possibly M. leprae infected individuals, CCL4WCS and IP-
10WCS were selected as immune markers since these single tests were more frequently positive in patients 
(MB and PB) compared to contacts (HCC and HCC&BCG) and are therefore associated with pathogenic 
immunity to M. leprae. The combination of CCL4WCS and IP-10WCS indeed demonstrated a positive test 
result more often in patients than in HHC or EC (Fig. 4b), whereas the related AUCs were ≥ 0,66 thus con-
firming leprosy disease-specificity (Supplementary Table S4B).
(III) For classification of leprosy a signature consisting of anti-PGL-I IgM, IL-10WCS and IP-10Nil was applied, as 
each of these markers individually showed more positive test results in MB patients compared to PB patients 
(Fig. 3). This profile proved to be specific for MB patients (Fig. 4c) and thereby allowed the differentiation of 
MB and PB patients (AUC = 0.73, Supplementary Table S4C).
Ideally only one multicomponent host biomarker profile for diagnosis of M. leprae infection, leprosy per 
se and leprosy classification would be more suitable for field-use. In this exploratory study, a 4 marker pro-
file of IL-10WCS, IP-10Mlep, CCL4WCS and anti-PGL-I IgM was selected for this purpose, enabling distinction of 
infected and non-infected individuals by IL-10WCS, IP-10Mlep and CCL4WCS, MB and PB patients from HHC 
and EC by CCL4WCS and MB from PB patients by anti-PGL-I IgM and IL-10WCS (Fig. 4d; Supplementary Table 
S4D). However, to distinguish MB from PB patients or PB patients from HHC profile III for leprosy clas-
sification showed a higher AUC compared to the 4 marker profile (0.73 vs. 0.65 and 0.66 vs. 0.62 respectively, 
Supplementary Table S4). These data indicate the importance of distinct phase-specific profiles, the application of 
which will depend on the nature of the diagnosis to be made.
Nonetheless, application of the 4 marker profile demonstrated the influence of multicomponent host bio-
marker profiles on test accuracy, showing increased AUCs compared to individual markers (Supplementary 
Figure S1). The added value of using various analytes indicates the potential of multicomponent host biomarker 
profiles for leprosy diagnostics to detect M. leprae infection, leprosy disease or disease classification.
Discussion
The obvious incessant transmission of M. leprae has brought about increased focus in leprosy research on discov-
ery of biomarkers to improve diagnosis. Nevertheless, thus far only few biomarkers for leprosy are recommended 
Figure 4. Potential of biomarker profiles to indicate M. leprae infection, disease per se and disease 
classification. The amount of positive test results per group is shown. (a) IP-10Mlep, CCL4WCS and IL-10WCS 
significantly differed in MB/PB patients and (BCG-vaccinated) HHC from EC, showing more positive test 
results in the groups that are exposed to M. leprae and thereby indicating M. leprae infection. (b) CCL4WCS 
and IP-10WCS enabled the distinction between patients and HHC, thereby indicating the pathogenic immune 
responses to M. leprae in patients. (c) Anti-PGL-I IgM, IL-10WCS and IP-10Nil showed more positive test results 
in MB patients thereby enabling the distinction between MB and PB patients. (d) A four marker profile of IL-
10WCS, IP-10Mlep, CCL4WCS and anti-PGL-I IgM shows the majority of significant differences observed in A, B 
and C. P-values: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
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by expert panels11. Consequently, there is a growing need for new and sensitive diagnostic tools based on specific 
biomarkers which should, ideally, allow straightforward translation into field-friendly tests.
In this exploratory study, we aimed to provide several multicomponent host immune-biomarker profiles 
which distinguish between distinct stages of M. leprae infection. In this process we also emphasized the chal-
lenges that need to be tackled to allow application of these biomarkers in the field. As high-tech laboratories are 
often lacking in leprosy endemic areas, we examined the diagnostic potential of earlier developed field-friendly 
UCP-LFAs for detection of anti-PGL-I IgM antibodies and cyto/chemokines IP-10, IL-10 and CCL424,28,31, in an 
extensive cohort in Bangladesh.
We demonstrated the biomarker potential of IP-10, IL-10, CCL4 and anti-PGL-I IgM measured by UCP-LFAs 
in whole blood, either in response to M. leprae specific stimuli or without stimulus. Moreover, multicomponent 
host biomarker profiles including selected analyte/stimulus combinations could indicate M. leprae infection, 
leprosy per se or be used for classification of leprosy subtypes. A biomarker profile of IP-10Mlep, CCL4WCS and 
IL-10WCS was highly indicative of M. leprae infection, consistent with our previous finding that the IP-10 response 
to M. leprae specific proteins indicates exposure to M. leprae16,32.
Leprosy per se, on the other hand, was indicated by CCL4WCS and IP-10 WCS, showing the potential to identify 
pathogenic immunity against M. leprae and confirming earlier observations on CCL416. As current diagnostic 
assays for leprosy are antibody-based and only facilitate the diagnosis of MB cases33–35, inclusion of the host 
immune markers CCL4 and IP-10 in the profile shows promise for diagnosis of PB patients and indicates the 
importance of measuring cellular markers simultaneously with humoral markers.
For leprosy classification, the combination of anti-PGL-I IgM, IL-10WCS and IP-10Nil was indicative 
for MB patients, enabling the distinction between MB and PB patients. Although IL-10 and particularly 
anti-PGL-I IgM have been identified as characteristic markers for MB leprosy36,37, we also identified IP-10 
as a, seemingly counterintuitive, host immune marker for patients at this side of the spectrum who usually 
display decreased pro-inflammatory immunity. However, since T-cells are not the exclusive source of IP-1038, 
IP-10 may still be produced in MB patients by monocytes and neutrophils39, as described for HIV-infected 
TB patients40.
To detect M. leprae infection, leprosy per se, as well as leprosy classification simultaneously with only one 
biomarker profile, IL-10WCS, IP-10Mlep, CCL4WCS and anti-PGL-I IgM demonstrated the most optimal 4 marker 
profile performance. However, it performed less optimal for the distinct stages of M. leprae infection than the 
phase-specific profiles. Other cyto-/chemokines to identify pathogenic immunity to M. leprae (e.g. MCP-1 and 
IL-1β 16), leprosy classification (e.g. CCL17 and CCL1841) or general mycobacterial infection (EN-RAGE42,43) 
could therefore be included to achieve more optimal diagnostic accuracy44 as distinct phase-specific profiles. In 
a multiplex UCP-LFA format multicomponent host immune biomarker profiles can be measured in one single 
test. This format therefore provides a field-friendly diagnostic tool, facilitating the diagnosis of leprosy based on 
biomarker signatures.
Of note is the observation that CCL4 levels in response to M. leprae WCS were elevated for HHC who 
received BCG vaccination compared to those who did not. Thus, BCG vaccination may also cause increased 
pro-inflammatory immune responses which renders contacts more prone to development of over-reactive, 
pathogenic immunity to M. leprae. Indeed, in a recent vaccination study an unexpectedly high proportion of 
HHC presented with PB leprosy after BCG vaccination supporting this idea45. In this respect, this vaccination 
study also shows the importance of immunomonitoring individuals at high risk to identify and treat patients 
at an early stage. In addition, since BCG vaccination or boost is a well-accepted prophylaxis against leprosy in 
contacts of newly diagnosed patients46, it is relevant to distinguish BCG-induced immunity in healthy contacts 
from early stage leprosy in these individuals. To efficiently monitor contacts for this purpose, the different stages 
of infection and disease of leprosy should be covered in diagnostics tools. Through simultaneous measurement 
of all analytes of interest on a single lateral flow strip, this format allows assessment of multicomponent host bio-
marker profiles using a unique field-friendly technology24,29,31. Thereby, the UCP-LFA format not only provides 
diagnostic tools for leprosy but similarly holds promise for TB diagnosis28 and immunomonitoring of other 
chronic diseases31.
Materials and Methods
Study participants. Participants were recruited on a voluntary basis between January 2013 and December 
2014 in leprosy endemic areas in Bangladesh as described previously30. Leprosy was diagnosed based on clinical, 
bacteriological and histological observations and classified by skin smears according to Ridley and Jopling14. 
Clinical and demographic data was collected in a database. Participants were classified into six test groups; MB 
patients, PB patients, HHC, HHC&BCG, NC and EC. Control individuals from the same leprosy endemic area 
(EC) were examined for the absence of clinical signs and symptoms of leprosy and TB; staff of leprosy- or TB 
clinics were excluded.
Test group selection. A randomized sample selection was taken from 1110 participants30. Individuals were 
randomly assigned for sample inclusion using the RAND formula (Excel 2010), aiming for a 50/50 male/female 
ratio and a 1:1:1 ratio of three age groups: 0–14, 15–29, and 30+ (Supplementary Table S1). In total 242 individ-
uals were selected; MB patients (n = 34), PB patients (n = 45), HHC (n = 54), HHC&BCG (n = 50), EC (n = 51) 
and NC (n = 8; PB = 7, MB = 1). Patient characteristics are shown in Supplementary Table S2.
Leprosy prevalence. During this study the prevalence in the four districts (Nilphamari, Rongpur, 
Ponchagor en Thakurganch) was 0.82 per 10,000 with a new case detection rate of 0.98 per 10,000 (monthly 
report of Rural Health Program of 4 districts of Nilphamari, Bangladesh).
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Whole blood assay (WBA). Upon recruitment venous, heparinized blood (4 ml) was used directly in whole 
blood assays (WBA), using microtubes pre-coated with M. leprae whole cell sonicate (designated WCS), ML2478/
ML0840 recombinant proteins (designated Mlep)16 or without antigen stimulus (designated Nil)30. After 24 hour 
incubation at 37 °C materials were frozen at − 20 °C, shipped on dry ice to the LUMC and stored at − 80 °C until 
analysis by ELISA or UCP-LFA24.
PGL-I and M. leprae whole cell sonicate (WCS). Synthesized disaccharide epitope (3,6-di-O-methyl-β - 
D-glucopyranosyl(1 → 4)2,3-di-O-methylrhamnopyranoside), similar to M. leprae specific PGL-I glycolipid, 
coupled to human serum albumin (synthetic PGL-I; designated ND-O-HSA) and M. leprae whole cell sonicate 
(WCS) generated with support from the NIH/NIAID Leprosy Contract N01-AI-25469 were obtained through 
the Biodefense and Emerging Infections Research Resources Repository (http://www.beiresources.org/
TBVTRMResearchMaterials/tabid/1431/Default.aspx)47.
PGL-I ELISA. IgM antibodies against M. leprae PGL-I were detected as previously described19. Absorbance of 
horseradish peroxidase (HRP) was determined at a wavelength of 450 nm.
ELISA for IL-10, IP-10 and CCL4. IP-10 (851.870.015, Diaclone Research, Besancon, France), IL-10 (851.540.015, 
Diaclone Research, Besancon, France) and CCL4 (DY271-05, R&D systems, Minneapolis, USA) ELISA kits 
were used. ELISA testing was performed according to the manufacturer’s protocol using coating antibody clones 
B-S10, B-C50 and #24006 and detection antibodies B-T10, BC-55 and BAF271 respectively for IL-10, IP-10 and 
CCL4. HRP absorbance was determined at wavelength of 450 nm.
UCP-LFA for IL-10, IP-10 and CCL4. UCP-LFAs for CCL4, IL-10 and IP-10 were prepared and per-
formed as described previously24,28,29. The same antibody pairs as used for ELISAs were applied, with the 
non-biotinylated variant of the detection antibodies (non-biotinylated CCL4: AF-271-NA). Briefly, mixtures of 
100 ng cytokine-specific UCP reporter conjugate and diluted serum sample (1:4 for IL-10, 1:30 for IP-10 and 
1:300 for CCL4) were incubated for 60 min on a thermoshaker at 37 °C and 900 rpm. The mixture was then 
applied to cytokine-specific LF strips (containing a Test line with an antibody complementary to the antibody 
on the UCP particles) and immunochromatography was allowed to continue until strips were dry. LF strips were 
scanned in a Packard FluoroCount microtiterplate reader adapted for measurement of the UCP label (980 nm IR 
excitation, 550 nm emission). Results are displayed as the ratio value between Test and Flow-Control signal based 
on relative fluorescence units (RFUs) measured at the respective lines48. Ratio values were translated to concen-
tration based on standard curves for each immunemarker. Lower limit of detection was 32 pg/ml for IL-10 and 
316 pg/ml for IP-10 and CCL4.
To determine test positivity, similar wholeblood samples from a set of healthy, non-endemic control individu-
als (NEC) were analysed and UCP-LFA thresholds were calculated based on the average value of all NEC samples 
(Supplementary Table S3).
UCP-LFA for anti-PGL-I antibody. For detection of anti-PGL-I IgM antibodies, the same protocol as used 
for cytokine detection was applied utilizing 100-fold diluted serum and IgM-specific UCP conjugate (UCPαIgM). 
Only unstimulated samples were analysed as the level of antibody levels does not change upon antigen stimula-
tion. The threshold for positivity of 0.29 was determined by computing receiver operating characteristic (ROC) 
curves.
Ethics. This study was performed according to the Helsinki Declaration as described previously30. The 
national Research Ethics Committee (Bangladesh Medical Research Council) has approved the study protocol 
(Ref no. BMRC/NREC/2010-2013/1534).
Participants were informed about the study-objectives, the samples and their right to refuse to take part or 
withdraw from the study without consequences for their treatment. Written informed consent was obtained 
before enrolment. All patients received treatment according to national guidelines.
ROC curves. Graphpad Prism version 6.02 for Windows (GraphPad Software, San Diego CA, USA) was used 
to plot ROC curves and calculate the area under curve (AUC); for IP-10, IL-10, and CCL4 the concentrations 
(pg/ml) were applied, whereas for anti-PGL-I IgM the OD450 corrected for background (ELISA) and ratio value 
(UCP-LFAs) was used.
Statistical analysis. Differences in cytokine or antibody levels between test groups, as determined with 
UCP-LFA, were analysed with the One-way ANOVA for non-parametric distribution (Kruskall-Wallis) and Dunn’s 
correction for multiple testing using GraphPad Prism. For IP-10, IL-10 and CCL4 the concentrations (pg/ml) 
and for anti-PGL-I IgM the UCP-LFA ratio values were utilized. The statistical significance level used was 
p ≤ 0.05.
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